-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3815 Safety and Efficacy of Non-Irradiated Granulocyte Transfusions (GTX) in Neutropenic Patients with Severe or Refractory Abdominal Infections: A Single Center Retrospective Analysis of 119 Transfusions in 22 Patients

Program: Oral and Poster Abstracts
Session: 401. Basic Science and Clinical Practice in Blood Transfusion: Poster III
Hematology Disease Topics & Pathways:
Adult, Biological, viral, Diseases, Therapies, bacterial, Study Population, Infectious Diseases, Clinically relevant, Lymphoid Malignancies, Myeloid Malignancies, transfusion
Monday, December 3, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Guillaume Richard-Carpentier, MD1, Hagop M. Kantarjian, MD1, Farhad Ravandi, MBBS2, Tapan M. Kadia, MD3, Gautam Borthakur, MD1, Guillermo Garcia-Manero, MD4, Courtney D. DiNardo, MD, MSc5, William G. Wierda, MD, PhD1, Naval G. Daver, MD1, Naveen Pemmaraju, MD1, Prithviraj Bose, MD6, Marina Y. Konopleva, MD, PhD6, Michael Andreeff, MD, PhD1, Srdan Verstovsek, MD, PhD1, Heidi M Krause7*, Fleur M. Aung, MD7* and Jorge E. Cortes, MD1*

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
4Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
5Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, MD Anderson Cancer Center, Houston, TX
7Department of Laboratory Medicine, Section of Transfusion Medicine / Blood Donor Center, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Background: Neutropenic patients with hematologic malignancies are at high risk of infectious related-deaths. Granulocyte transfusions (GTX) are used in neutropenic patients to treat severe refractory infections. These blood products are usually irradiated to eliminate T-cells that can cause transfusion-associated graft-versus-host disease (TA-GVHD) in severely immunocompromised patients. We adopted a strategy of rapid utilization of non-irradiated GTX in neutropenic patients with severe abdominal infection to accelerate recovery and prevent infectious-related deaths. We report here the safety and efficacy data of 119 transfusions administered in 22 patients with abdominal infections.

Methods: We retrospectively analyzed the safety and efficacy data of patients with abdominal infections who received non-irradiated GTX in our institution between January 1st 2015 and December 31st 2017. Patients with hematological malignancies, severe neutropenia (<0.5 x 109/L) and severe abdominal infection would receive GTX until neutrophils increase > 1.0 x 109/L or significant clinical improvement. Granulocyte donors were mobilized using subcutaneous G-CSF 480 mcg and 8 mg of oral dexamethasone regardless of ABO and HLA compatibility. ABO incompatible GTX were drained of red cells prior to transfusion. We collected increments of absolute neutrophil counts (ANC) after each GTX, number of days with ANC > 1.0 x 109/L and transfusion-related complications. Controlled infection was defined as significant clinical improvement or antibiotic de-escalation or end.

Results: A total of 119 non-irradiated GTX were administered in 22 patients for 25 different infectious episodes. Baseline characteristics of patients are summarized in table 1. Median age of patients was 53.5 year-old (range 21 to 73) and 12 patients (54.5%) were male. Most patients had acute myeloid leukemia (14/22 patients, 63.6%) and relapsed disease (13 patients). GTX were administered in 11 patients (44%) for neutropenic enterocolitis, 6 (24%) for small bowel obstruction and/or perforation, 5 (20%) for clostridium difficile colitis, 2 (8%) for abdominal abscesses and 1 (4%) for appendicitis. Patients received a median of 3 GTX during their infectious episode (range 1 to 17). The median ANC before first GTX was 0.1 x 109/L (range 0.0 to 4.5). After GTX, there was a median increase in ANC of 0.3 x 109/L (range -0.8 to 26.1), with the peak of ANC occurring at a median of 24 hours after first GTX and returning to baseline at a median of 2 days after the last GTX. In 15 patients (68%), ANC was above 1 x 109/L for 3 days or more. GTX contributed to control infection in 19 infectious episodes (76%) after a median of 5 days following first transfusion (range 2 to 32 days). There was no significant association between sex, infectious diagnosis, initial ANC, number of GTX, mean ANC increment per patient or ANC > 0.1 x 109/L for 3 days and the rate of controlled infection 7 days after first GTX. Twelve patients (54.5%) were able to pursue their treatments without significant delays (> 7 days) after their infectious episode. Five patients (22.3%) died with the active infection for which they had received a GTX; all these patients also had active refractory disease and severe comorbidities. The median overall survival (OS) from first GTX was 7.7 months (95% CI; 2.7 to 17.4). Patients who had a controlled infection within 7 days of first GTX had significantly better OS (median OS 12.4 months vs. 1.6 months, log-rank p < 0.001) (Figure 1). Pulmonary events leading to death were reported in 2 patients; one had acute respiratory distress syndrome and cardiac arrest the day after the first GTX, but had pneumonia before transfusion, and one had worsening of pre-existing lung infiltrates 3 days after GTX and eventually died of respiratory failure. Importantly, no TA-HSCT were reported in the medical notes, neither suspected by the review of the patients’ charts.

Conclusion: Non-irradiated GTX are safe and effective to control severe abdominal infection. Noteworthy, no TA-GVHD occurred in this cohort of severely immunocompromised patients. Pulmonary complications after GTX are rare but can be serious, mostly seen in patients with pre-existing pulmonary infiltrates. GTX in such instances may pose higher risks. Further studies are needed to evaluate the comparative safety and efficacy of non-irradiated GTX with irradiated GTX.

Disclosures: Kantarjian: Pfizer: Honoraria, Research Funding; Orsenix: Honoraria; Novartis: Research Funding; Immunogen: Honoraria; BMS: Honoraria, Research Funding; Astex: Research Funding; ARIAD: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Actinium: Honoraria; AbbVie: Honoraria. Ravandi: Xencor: Research Funding; Sunesis: Honoraria; Macrogenix: Honoraria, Research Funding; Jazz: Honoraria; Astellas Pharmaceuticals: Consultancy, Honoraria; Xencor: Research Funding; Seattle Genetics: Research Funding; Seattle Genetics: Research Funding; Amgen: Honoraria, Research Funding, Speakers Bureau; Jazz: Honoraria; Orsenix: Honoraria; Bristol-Myers Squibb: Research Funding; Sunesis: Honoraria; Orsenix: Honoraria; Amgen: Honoraria, Research Funding, Speakers Bureau; Abbvie: Research Funding; Bristol-Myers Squibb: Research Funding; Macrogenix: Honoraria, Research Funding; Abbvie: Research Funding; Astellas Pharmaceuticals: Consultancy, Honoraria. Kadia: Takeda: Consultancy; BMS: Research Funding; Abbvie: Consultancy; Novartis: Consultancy; Jazz: Consultancy, Research Funding; Amgen: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Novartis: Consultancy; BMS: Research Funding; Abbvie: Consultancy; Amgen: Consultancy, Research Funding; Celgene: Research Funding; Pfizer: Consultancy, Research Funding; Takeda: Consultancy; Celgene: Research Funding. DiNardo: Bayer: Honoraria; Agios: Consultancy; Abbvie: Consultancy; Celgene: Consultancy; Medimmune: Honoraria; Karyopharm: Honoraria; Jazz: Honoraria; Syros: Honoraria. Wierda: AbbVie, Inc: Research Funding; Genentech: Research Funding. Daver: ARIAD: Research Funding; Otsuka: Consultancy; Incyte: Consultancy, Research Funding; Daiichi-Sankyo: Consultancy, Research Funding; Pfizer: Research Funding; Alexion: Consultancy; ImmunoGen: Consultancy, Research Funding; Sunesis: Consultancy; BMS: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Novartis: Research Funding; Kiromic: Research Funding; Incyte: Consultancy, Research Funding; Karyopharm: Consultancy, Research Funding; Novartis: Consultancy, Research Funding. Pemmaraju: abbvie: Research Funding; samus: Research Funding; daiichi sankyo: Research Funding; plexxikon: Research Funding; stemline: Consultancy, Honoraria, Research Funding; celgene: Consultancy, Honoraria; Affymetrix: Research Funding; cellectis: Research Funding; novartis: Research Funding; SagerStrong Foundation: Research Funding. Bose: Incyte Corporation: Honoraria, Research Funding; Astellas Pharmaceuticals: Research Funding; Constellation Pharmaceuticals: Research Funding; CTI BioPharma: Research Funding; Pfizer, Inc.: Research Funding; Celgene Corporation: Honoraria, Research Funding; Blueprint Medicines Corporation: Research Funding. Konopleva: Stemline Therapeutics: Research Funding. Andreeff: Celgene: Consultancy; Daiichi-Sankyo: Consultancy, Patents & Royalties: MDM2 inhibitor activity patent, Research Funding; Amgen: Consultancy, Research Funding; Jazz Pharma: Consultancy; SentiBio: Equity Ownership; Oncolyze: Equity Ownership; Aptose: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Oncoceutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Reata: Equity Ownership; United Therapeutics: Patents & Royalties: GD2 inhibition in breast cancer ; Eutropics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Research Funding. Verstovsek: Italfarmaco: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy. Cortes: Novartis: Consultancy, Research Funding; Astellas: Consultancy, Research Funding; Daiichi: Consultancy, Research Funding; AROG: Research Funding.

*signifies non-member of ASH